I don't know about you, but I'm pretty stoked for the NFL draft this Thursday. As an avid Detroit Lions fan, I begrudgingly admit that I'm very familiar with the triumphs and failures of draft day having endured quite a few high-ranking selections over the past decade.
Keeping with the spirit of the upcoming NFL draft, I thought it would be a fun exercise to essentially "draft" the perfect biotech company. What I intend to do is break the biotech sector into three basic components -- the CEO position, the lead drug, and the blockbuster pipeline candidate -- and select what I feel would be an all-star biotechnology company.
The CEO
The success of a biotech company all begins with its leader. A biotech CEO is the person who's ultimately responsible for the success of a company's pipeline and the launch of any drugs approved by the Food and Drug Administration. In this category, there isn't a CEO that I'd rather have leading my biotech dream team than Biogen Idec's (NASDAQ: BIIB ) George Scangos.
Top Services Companies To Own For 2015: RingCentral Inc (RNG)
RingCentral, Inc., incorporated on February 9, 1999, is a provider of software-as-a-service (SaaS) solutions for business communications. RingCentral Office, the Company�� flagship service, is a multi-user, enterprise-grade communications solution that enables its customers and their employees to communicate through voice, text and fax, on multiple devices, including Smartphone��, tablets, personal computers (PCs) and desk phones. The Company also offer RingCentral Professional, primarily an inbound call routing service with additional text and fax capabilities targeting smaller deployments, and RingCentral Fax, an Internet fax service that permits sending and receiving faxes over the Internet.
The Company�� solutions have been developed with a mobile-centric approach and can be configured, managed and used from a Smartphone or tablet. The Company�� solutions generally use existing broadband connections. The Company�� cloud-based business communications solutions provide a single user identity across multiple locations and devices, including smartphone, tablets, PCs and desk phones, and allow for communication across multiple channels, including voice, text and fax. The Company primarily generate revenues by selling subscriptions for our cloud-based services.
The Company competes with Alcatel-Lucent, S.A., Avaya Inc., Cisco Systems, Inc., Mitel Networks Corporation, ShoreTel, Inc., Siemens Enterprise Networks, LLC, Microsoft Corporation, Broadsoft, Inc., AT&T Inc., Verizon Communications Inc., Comcast Corporation, j2 Global, Inc., 8x8, Inc., Google Inc., Yahoo! Inc. and Amazon.com.
Advisors' Opinion:- [By Paul Ausick]
Stocks on the Move: J.C. Penney Co. Inc. (NYSE: JCP) is down 13.9% at $8.97 after a secondary stock offering�that might have been designed to drive out short sellers. Violin Memory Inc. (NASDAQ: VMEM) is down 21% at $7.11 on a lousy IPO�day. RingCentral Inc. (NYSE: RNG) is up 39.5% at $18.14 on a good IPO day.
10 Best Prefered Stocks To Buy Right Now: Australia and New Zealand Banking Group Ltd (ANEWF)
Australia and New Zealand Banking Group Limited (ANZ) provides a range of banking and financial products and services to retail, small business, corporate and institutional clients. The Company conducts its operations in Australia, New Zealand and the Asia Pacific region. It also operates in a range of other countries, including the United Kingdom and the United States. The Company operates on a divisional structure with Australia, International and Institutional Banking (IIB), New Zealand, and Global Wealth and Private Banking. As of September 30, 2012, the Company had 1,337 branches and other points of representation worldwide, excluding automatic teller machines (ATMs). In September 2012, it sold its remaining shareholding in Visa Inc. In May 2013, the Company ceased to be substantial holder in respect of ING Private Equity Access Limited. Advisors' Opinion:- [By WWW.MARKETWATCH.COM]
LOS ANGELES (MarketWatch) -- Australia shares nudged lower early Friday, with the S&P/ASX 200 (AU:XJO) down 0.2% to erase the previous session's 0.2% gain, dragged by losses for European and U.S. equities on the back of a Portuguese financial crisis. Financials fell (Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) and National Australia Bank Ltd. (AU:NAB) (NAUBF) each down 0.3%, Commonwealth Bank of Australia (AU:CBA) (CBAUF) down 0.4%, and Macquarie Group Ltd. (AU:MQG) (MCQEF) down 0.7%), and the top miners fared especially poorly (Rio Tinto Ltd. (AU:RIO) (RIO) down 1.2%, Oz Minerals Ltd. (AU:OZL) (OZMLF) down 1.1%, though BHP Billiton Ltd. (AU:BHP) (BHP) off just 0.1%). And while Atlas Iron Ltd. (AU:AGO) beat its production guidance, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) missed its production guidance, both saw losses, with Atlas stock off 2.9% and Fortescue trading 1.6% lower. Among the gainers, Scentre Group
- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Stocks in Australia fell early Thursday, pressured by a drop in the country's currency to a three-month low below 90 U.S. cents, and by losses on Wall Street overnight on concerns about tapering of monetary stimulus. The S&P/ASX 200 (AU:XJO) fell 28 points, or 0.5%, to 5,246, led by losses in the heavily weighted financial sector. There, shares of Westpac Banking Corp. (AU:WBC) (WEBNF) lost 1.2%, National Australia Bank Ltd. (AU:NAB) (NAUBF) declined 1%, and Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) shed 0.7%. Shares of Qantas Airways Ltd. (AU:QAN) (QUBSF) sank 14% after the company warned it expects to post an underlying loss before tax of $250 million to $300 million for the six months ending Dec. 31. The carrier said trading conditions saw a marked deterioration, particularly in November with both passenger loads and yields "below the already negative trends for the year to date."
10 Best Prefered Stocks To Buy Right Now: LivePerson Inc.(LPSN)
LivePerson, Inc. provides online engagement solutions that facilitate real-time assistance and expert advice in the United States, Canada, Latin America, Europe, and the Asia-Pacific region. The company facilitates real-time online interactions, such as chat, voice/click-to-call, email, and self-service/knowledgebase for corporations of various sizes; and connects businesses and independent service providers with individual consumers seeking help on its hosted software platform. Its products and services comprise LP Chat that creates real-time connections for businesses to connect with consumers through Websites, social media, and mobile devices; LP Voice, which provides customers a connection between a Website and the voice channel to engage prospects and consumers online; and LivePerson Expert Platform, a marketplace platform that allows users to chat live with independent experts in various categories. The company?s products and services also include LP Marketer that o ffers a real-time data-driven targeting solution that delivers personalized digital user experiences; and LP Insights, which provide customers with a text analytics tool that enables them to data mine for ?Voice of the Customer? and ?Voice of the Agent? content. In addition, it offers provides professional services and value-added business consulting services. The company sells its products through direct and indirect sales channels to small and mid-sized businesses, Internet businesses, online merchants, universities, libraries, government agencies, and not-for-profit organizations, as well as to financial, retail, telecommunications, technology, and travel/hospitality industries. LivePerson, Inc. was founded in 1995 and is headquartered in New York, New York.
Advisors' Opinion:- [By Brendan Byrnes]
The following video excerpt was taken from an interview with Robert LoCascio, founder and CEO of LivePerson (NASDAQ: LPSN ) , as he talks about what was behind the company's incredible success story. In this segment, he explains the company's opportunities for international expansion. �
10 Best Prefered Stocks To Buy Right Now: iShares S&P 500 Value Index Fund (IVE)
iShares S&P 500 Value Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor's 500/Citigroup Value Index (the Index). The Index measures the performance of the large-capitalization value sector of the United States equity market. It is a subset of the Standard & Poor's 500 Index, and consists of those stocks exhibiting the strongest value characteristics in the Standard & Poor's 500 Index, representing approximately 51% of the market capitalization of the Standard & Poor's 500 Index.
The Fund uses a representative sampling strategy in seeking to track the Index. Barclays Global Fund Advisors (BGFA) serves as an advisor to the Fund.
Advisors' Opinion:- [By David Fabian]
In addition, this sector has likely benefited from the rotation out of high-beta growth stocks and into value-oriented segments that are more defensive in nature.� The energy sector is the second largest allocation in the iShares S&P 500 Value ETF (NYSE: IVE), with more than 15 percent of the underlying holdings.�
10 Best Prefered Stocks To Buy Right Now: LDK Solar Co. Ltd.(LDK)
LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.
Advisors' Opinion:- [By Travis Hoium]
What: Shares of LDK Solar (NYSE: LDK ) fell 11% today after the company issued its first-quarter earnings report.
So what: Sales during the quarter were just $104.3 million on shipments of 240 MW of wafers and 31.4 MW of cells and modules. Net loss was a whopping $187.1 million, or $1.21 per share. �
10 Best Prefered Stocks To Buy Right Now: Protalix Biotherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.
Taliglucerase Alfa
Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.
PRX-102
The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.
Acetylcholinesterase
Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.
As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.
pr-antiTNF
pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.
The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.
Advisors' Opinion:- [By Keith Speights]
Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."
10 Best Prefered Stocks To Buy Right Now: Westell Technologies Inc.(WSTL)
Westell Technologies, Inc., through its subsidiaries, engages in the design, distribution, marketing, and servicing a range of broadband, digital transmission, remote monitoring, power distribution, and demarcation products used by telephone companies and other telecommunications service providers. It operates in three segments: Customer Networking Systems (CNS) equipment, Outside Plant Systems (OSP) equipment, and ConferencePlus services. The CNS equipment segment provides networking and high-speed transmissions products, such as modems, routers, versatile gateway devices, and wireless broadband home routers that allow service providers to deliver broadband services over existing copper, fiber, coax, or wireless infrastructures. The OSP segment offers next generation outdoor cabinets; enclosures; power distribution; fiber, Ethernet, and coax edge connectors; remote monitoring equipment; and DS1 and DS3 transmission plugs. This segment also markets and sells power distribu tion and remote monitoring solutions. The ConferencePlus services segment provides audio, Web, and video conferencing services to businesses and individuals. This segment sells its services directly to Fortune 1000 companies, and indirectly through its private reseller programs. The company offers its products through field sales organizations and selected distributors in the United States, as well as in Canada and Europe. Westell Technologies, Inc. was founded in 1980 and is headquartered in Aurora, Illinois.
Advisors' Opinion:- [By Rich Smith]
Late last month, the networking equipment maker had to scramble when its acting chief financial officer, Tom Minichiello, announced plans to retire on July 12 to become the new CFO at Westell Technologies (NASDAQ: WSTL ) . On Friday, though, just as the deadline was happening, Tellabs announced that it has found a replacement.
No comments:
Post a Comment